PTHS Form 4: Director Granted 77,338 Shares at $13.50 Post-Split

Q: How many Pelthos Therapeutics (PTHS) shares were granted to Richard Malamut?

He received 19,108 RSUs and 58,230 stock options post-reverse-split.

Q: When do the newly granted RSUs and options begin vesting?

They vest quarterly, starting on 2 July 2026, and will be fully vested after three years.

Q: Did the Form 4 report any open-market sales or purchases?

No. The filing only records equity awards鈥攏o cash transactions were reported.

Q: How was the share count affected by Pelthos鈥檚 reverse stock split?

All numbers in the filing reflect the 1-for-10 reverse split completed on 1 July 2025.

[SCHEDULE 13D/A] Sinovac Biotech, Ltd SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

Form 4 filing 鈥� Pelthos Therapeutics Inc. (PTHS)

Director Richard Malamut reported two equity awards dated 2 July 2025 following the company鈥檚 1-for-10 reverse stock split on 1 July 2025:

19,108 Restricted Stock Units (RSUs) convertible into common shares at an exercise price of $13.50; vest quarterly over three years, first vesting 2 July 2026.
58,230 Stock Options with a $13.50 strike price; identical quarterly vesting over three years and an expiration date of 2 July 2035.

Post-grant, Malamut holds 28,012 RSUs and 58,230 options, all in direct ownership. The filing records no open-market purchases or sales鈥攐nly compensation-related grants鈥攕o immediate cash flow impact is nil. The awards modestly increase the company鈥檚 fully-diluted share count yet strengthen director-shareholder alignment by tying compensation to long-term share performance.

Positive

Director alignment: Quarterly-vesting RSUs and options tie compensation to future share performance.
Transparent disclosure: Form 4 details reverse-split adjustments and Rule 10b5-1 compliance, reducing governance risk.

Negative

Potential dilution: Issuance of 77,338 additional equity instruments marginally increases the fully-diluted share count.

Insights

TL;DR 鈥� Compensation grants, no cash trades; limited dilution, better alignment.

The 77,338 post-split equity instruments represent a routine director compensation package. Because the strike price equals the company-set grant price of $13.50, the options are only valuable if shares appreciate, which aligns incentives. Dilution is marginal given Pelthos鈥檚 likely multi-million-share base, but investors should add the shares to fully-diluted models. No insider selling occurred, so the filing does not signal negative sentiment. Overall impact: neutral-slightly positive governance signal.

TL;DR 鈥� Standard equity package enhances alignment; governance practices intact.

The grant follows a recent 1-for-10 reverse split, showing the board promptly adjusted equity plans to preserve intended incentive value. Quarterly vesting over three years promotes retention while avoiding excessive front-loading. Full disclosure of Rule 10b5-1 language and precise share adjustments demonstrates compliance, lowering governance risk. The only caveat is minor dilution, typical for equity-heavy compensation programs. Overall, the filing is governance-positive but financially immaterial.

07/07/2025 - 09:41 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

SINOVAC BIOTECH LTD

(Name of Issuer)

Common Shares, par value $0.001 per share

(Title of Class of Securities)

P8696W104

(CUSIP Number)

1Globe Capital LLC
One International Place, 44th Fl,
Boston, MA, 02110
617-649-1157

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/07/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 搂搂 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

P8696W104

Name of reporting person

1Globe Capital LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,812,855.00
8	Shared Voting Power 11,702,460.00
9	Sole Dispositive Power 6,812,855.00
10	Shared Dispositive Power 11,702,460.00

Aggregate amount beneficially owned by each reporting person

18,515,315.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)

32.3 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

Comment for Type of Reporting Person: This Amendment No. 6 to Schedule 13D, or this Amendment, is being filed by 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited (each referred to herein as a reporting person, or together, referred to herein as the reporting persons) relating to the common shares, par value $0.001 per share, or the Common Shares, of Sinovac Biotech Ltd., the Issuer, a corporation organized under the laws of Antigua and Barbuda. This Amendment amends and supplements the Schedule 13D originally filed with the U.S. Securities and Exchange Commission, or the SEC, on July 7, 2017 and amended by Amendment No. 1 filed on March 26, 2018, Amendment No. 2 filed on March 19, 2019, Amendment No. 3 filed on December 21, 2020 Amendment No. 4 filed on July 1, 2025 and Amendment No. 5 filed on July 3, 2025 by 1Globe Capital LLC (as amended, referred to herein as the Schedule 13D). Amendment No. 5, filed on July 3, 2025, was intended to: (i) correct a typographical error in the number of shares reported as beneficially owned with sole voting power by 1Globe Biomedical (Hong Kong) Company Limited on the cover page of Amendment No. 4 and (ii) supplement the disclosures in items 4 and 6 of the Schedule 13D. However, while Amendment No. 5 did include the corrected cover page, the body of the filing inadvertently repeated some of the disclosures from Amendment No. 4 and omitted the intended updates to Items 4 and 6. This Amendment No. 6 corrects that oversight and sets forth the disclosures that were intended to be included in Amendment No. 5. Percentage of ownership in row 13 is calculated based on 57,281,861 shares outstanding as of December 31, 2017, as reported in the 2018 20-F. As described in Item 4 of this Schedule 13D, the issuance by the Issuer of the Exchange Shares (as defined in the 2019 20-F) and the Disputed PIPE (as defined in this Schedule 13D), among other things, are the subject of ongoing litigation, and therefore the shares outstanding does not include shares purportedly issued after May 2018.

SCHEDULE 13D

CUSIP No.

P8696W104

Name of reporting person

1Globe Biomedical (Hong Kong) Company Limited

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

HONG KONG

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,812,855.00
8	Shared Voting Power 11,702,460.00
9	Sole Dispositive Power 6,812,855.00
10	Shared Dispositive Power 11,702,460.00

Aggregate amount beneficially owned by each reporting person

18,515,315.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)

32.3 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

Comment for Type of Reporting Person: This Amendment No. 6 to Schedule 13D, or this Amendment, is being filed by 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited (each referred to herein as a reporting person, or together, referred to herein as the reporting persons) relating to the common shares, par value $0.001 per share, or the Common Shares, of Sinovac Biotech Ltd., the Issuer, a corporation organized under the laws of Antigua and Barbuda. This Amendment amends and supplements the Schedule 13D originally filed with the U.S. Securities and Exchange Commission, or the SEC, on July 7, 2017 and amended by Amendment No. 1 filed on March 26, 2018, Amendment No. 2 filed on March 19, 2019, Amendment No. 3 filed on December 21, 2020, Amendment No. 4 filed on July 1, 2025 and Amendment No. 5 filed on July 3, 2025 by 1Globe Capital LLC (as amended, referred to herein as the Schedule 13D). Amendment No. 5, filed on July 3, 2025, was intended to: (i) correct a typographical error in the number of shares reported as beneficially owned with sole voting power by 1Globe Biomedical (Hong Kong) Company Limited on the cover page of Amendment No. 4 and (ii) supplement the disclosures in items 4 and 6 of the Schedule 13D. However, while Amendment No. 5 did include the corrected cover page, the body of the filing inadvertently repeated some of the disclosures from Amendment No. 4 and omitted the intended updates to Items 4 and 6. This Amendment No. 6 corrects that oversight and sets forth the disclosures that were intended to be included in Amendment No. 5. Percentage of ownership in row 13 is calculated based on 57,281,861 shares outstanding as of December 31, 2017, as reported in the Issuer's Form 20-F filed with the U. S. Securities and Exchange Commission, or the SEC, on May 11, 2018 (referred herein as the 2018 20-F). As described in Item 4, the issuance by the Issuer of the Exchange Shares (as defined in the Issuer's Form 20-F filed with the SEC on April 29, 2019 (referred herein as 2019 20-F)) and the Disputed PIPE (as defined in this Schedule 13D), among other things, are the subject of ongoing litigation, and therefore the shares outstanding does not include shares purportedly issued after May 2018.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Shares, par value $0.001 per share

(b)

Name of Issuer:

SINOVAC BIOTECH LTD

(c)

Address of Issuer's Principal Executive Offices:

NO. 39 SHANGDI XI ROAD, HAIDIAN DISTRICT, BEIJING, CHINA , 100085.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On April 14, 2025, as part of the lawfare against and harassment of the current Board installed by the Privy Council's Order and per Antiguan law following the non-appealable ruling by the Privy Council, a purported shareholder in this Issuer, Vivo Capital Surplus Fund VIII, L.P., or Vivo, filed a civil action in the U.S. District Court for the District of Massachusetts against 1Globe Capital LLC and Jiaqiang Li. See Vivo Capital Surplus Fund VIII, L.P. v. 1Globe Capital LLC and JiaQiang Li, Civil Action No. 25-10914 (D. Mass.). This action mirrors the 2018 lawsuit filed by the same former management buyout group against the same defendants in Massachusetts, which was dismissed. The same plaintiff group has filed other actions in the U.S. District Court for the Southern District of New York and in the Hong Kong High Court against 1Globe Capital LLC and others, and their requests for preliminary relief have been uniformly dismissed. In this new action, the plaintiff alleges a disclosure violation claim under Section 13(d) of the Securities Exchange Act of 1934, alleging that Defendants failed to disclose: (1) any information relating to Li, including that he is not a passive investor; (2) 1Globe Capital LLC and Li's aggregate beneficial ownership of Issuer stock; (3) the formation of an alleged group among 1Globe Capital LLC, Li, OrbiMed, and others; (4) a description, in Item 4 of Schedule 13D, of their plans and proposals regarding the Issuer; and (5) a description, in Item 6 of Schedule 13D, of their arrangements, understandings or relationships with others with respect to shares of the Issuer. 1Globe Capital LLC and Li intend to vigorously defend against these Plaintiff's claim, which they contend are not supported by evidence and include falsified stories. The allegations discussed above and numbered (1), (2), (4) and (5) related to an SEC investigation in 2018 and were included in the settlement between the SEC and 1Globe Capital LLC and Li, where 1Globe Capital LLC and Li neither admitted nor denied findings and which were resolved five years ago in May 2020. That settlement was referenced in Amendment No. 3 to Schedule 13D filed on December 21, 2020. On June 30, 2025, the District Court denied Vivo "relief relating to governance outcomes and shareholder votes." In addition, the District Court granted, in part, its petition for preliminary relief, requiring, among other things, updated Schedule 13D disclosures. In response, 1Globe Capital LLC promptly filed Amendment No. 4, which, among other things, disclosed that, on June 27, 2025, the reporting persons started the process of casting their votes for the Special Meeting of the Issuer's shareholders to be held on July 8, 2025. 1Globe Capital LLC and Li plan to file a motion to dismiss and motion to dissolve. 1Globe Capital LLC will move to dismiss the Section 13(d) claim at the outset of the proceedings on the grounds that it has been pre-empted or rendered moot by Amendment No. 4 and subsequent amendments.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 4 of this Amendment is incorporated by reference in its entirety into this Item 6.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

1Globe Capital LLC

Signature:	/s/ Chiang Li
Name/Title:	Chairman
Date:	07/07/2025

1Globe Biomedical (Hong Kong) Company Limited

Signature:	/s/ Chiang Li
Name/Title:	Chairman
Date:	07/07/2025

Source:

FAQ

How many Pelthos Therapeutics (PTHS) shares were granted to Richard Malamut?

He received 19,108 RSUs and 58,230 stock options post-reverse-split.

What is the exercise price of the new PTHS options?

Both the RSUs (structured as purchase rights) and options carry a $13.50 exercise price.

When do the newly granted RSUs and options begin vesting?

They vest quarterly, starting on 2 July 2026, and will be fully vested after three years.

Did the Form 4 report any open-market sales or purchases?

No. The filing only records equity awards鈥攏o cash transactions were reported.

How was the share count affected by Pelthos鈥檚 reverse stock split?

All numbers in the filing reflect the 1-for-10 reverse split completed on 1 July 2025.

AG真人官方

[SCHEDULE 13D/A] Sinovac Biotech, Ltd SEC Filing

Insights

FAQ

How many Pelthos Therapeutics (PTHS) shares were granted to Richard Malamut?

What is the exercise price of the new PTHS options?

When do the newly granted RSUs and options begin vesting?

Did the Form 4 report any open-market sales or purchases?

How was the share count affected by Pelthos鈥檚 reverse stock split?

NASDAQ:SVA

SVA Rankings

SVA Latest News

SVA Latest SEC Filings

SVA Stock Data

AG真人官方

Trending News

[SCHEDULE 13D/A] Sinovac Biotech, Ltd SEC Filing

Insights

Securities Analyst neutral

Corporate Governance Expert positive

FAQ

How many Pelthos Therapeutics (PTHS) shares were granted to Richard Malamut?

What is the exercise price of the new PTHS options?

When do the newly granted RSUs and options begin vesting?

Did the Form 4 report any open-market sales or purchases?

How was the share count affected by Pelthos鈥檚 reverse stock split?

NASDAQ:SVA

SVA Rankings

SVA Latest News

SVA Latest SEC Filings

SVA Stock Data